Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
36
RARE Quote, Financials, Valuation and Earnings
Last price:
$34.57
Seasonality move
:
-0.96%
Day range:
$34.07 - $34.89
52-week range:
$25.81 - $46.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.28x
P/B ratio:
359.51x
Volume:
841.3K
Avg. volume:
1.4M
1-year change:
-22.2%
Market cap:
$3.3B
Revenue:
$560.2M
EPS (TTM):
-$5.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$166.8M | -$1.21 | 14.05% | -11.77% | $81.85 |
|
FBIO
Fortress Biotech, Inc.
|
$21M | -$0.31 | 24.34% | -72.5% | $10.75 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
GERN
Geron Corp.
|
$53.3M | -$0.04 | 7.03% | -8.38% | $3.60 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -0.81% | 32.75% | $789.90 |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.1B | $4.58 | 10.21% | 48.03% | $489.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$34.13 | $81.85 | $3.3B | -- | $0.00 | 0% | 5.28x |
|
FBIO
Fortress Biotech, Inc.
|
$3.60 | $10.75 | $111.7M | -- | $0.00 | 0% | 1.69x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.21 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.27x |
|
GERN
Geron Corp.
|
$1.33 | $3.60 | $849M | -- | $0.00 | 0% | 4.83x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$785.17 | $789.90 | $82.5B | 18.80x | $0.88 | 0.45% | 6.07x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$459.21 | $489.04 | $116.5B | 32.36x | $0.00 | 0% | 10.14x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
98.95% | 0.820 | 29.68% | 1.61x |
|
FBIO
Fortress Biotech, Inc.
|
55.01% | 1.103 | 55.12% | 1.93x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
GERN
Geron Corp.
|
50.25% | 1.700 | 28.73% | 4.76x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.58% | -0.151 | 1.84% | 1.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$123.3M | -$170.9M | -53.69% | -307.83% | -106.85% | -$92.7M |
|
FBIO
Fortress Biotech, Inc.
|
$10.7M | -$6.8M | -56.09% | -223.06% | -38.63% | -$6.1M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.7B | $1.3B | 20.08% | 22.13% | 41.02% | $1.1B |
Ultragenyx Pharmaceutical, Inc. vs. Competitors
-
Which has Higher Returns RARE or FBIO?
Fortress Biotech, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 50.07%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Fortress Biotech, Inc.'s return on equity of -223.06%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M FBIOFortress Biotech, Inc.60.8% $0.11 $133.5M -
What do Analysts Say About RARE or FBIO?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 139.82%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 198.61%. Given that Fortress Biotech, Inc. has higher upside potential than Ultragenyx Pharmaceutical, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Ultragenyx Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 FBIOFortress Biotech, Inc.2 0 0 -
Is RARE or FBIO More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.490, suggesting its more volatile than the S&P 500 by 49.031%.
-
Which is a Better Dividend Stock RARE or FBIO?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RARE or FBIO?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than Fortress Biotech, Inc. quarterly revenues of $17.6M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.28x versus 1.69x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.5.28x -- $159.9M -$180.4M FBIOFortress Biotech, Inc.1.69x -- $17.6M $8.8M
-
Which has Higher Returns RARE or FOLD?
Amicus Therapeutics, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 10.24%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About RARE or FOLD?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 139.82%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.32%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is RARE or FOLD More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock RARE or FOLD?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or FOLD?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.28x versus 7.27x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.5.28x -- $159.9M -$180.4M FOLDAmicus Therapeutics, Inc.7.27x -- $169.1M $17.3M
-
Which has Higher Returns RARE or GERN?
Geron Corp. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of -39.02%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About RARE or GERN?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 139.82%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 170.68%. Given that Geron Corp. has higher upside potential than Ultragenyx Pharmaceutical, Inc., analysts believe Geron Corp. is more attractive than Ultragenyx Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 GERNGeron Corp.3 1 1 -
Is RARE or GERN More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.
-
Which is a Better Dividend Stock RARE or GERN?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or GERN?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than Geron Corp. quarterly revenues of $47.2M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Geron Corp.'s net income of -$18.4M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.28x versus 4.83x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.5.28x -- $159.9M -$180.4M GERNGeron Corp.4.83x -- $47.2M -$18.4M
-
Which has Higher Returns RARE or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 38.89%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About RARE or REGN?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 139.82%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 0.6%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 REGNRegeneron Pharmaceuticals, Inc.14 8 0 -
Is RARE or REGN More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock RARE or REGN?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or REGN?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.28x versus 6.07x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.5.28x -- $159.9M -$180.4M REGNRegeneron Pharmaceuticals, Inc.6.07x 18.80x $3.8B $1.5B
-
Which has Higher Returns RARE or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 34.76%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M VRTXVertex Pharmaceuticals, Inc.86.69% $4.20 $19.2B -
What do Analysts Say About RARE or VRTX?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 139.82%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $489.04 which suggests that it could grow by 6.5%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 VRTXVertex Pharmaceuticals, Inc.17 10 1 -
Is RARE or VRTX More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.
-
Which is a Better Dividend Stock RARE or VRTX?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or VRTX?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.28x versus 10.14x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.5.28x -- $159.9M -$180.4M VRTXVertex Pharmaceuticals, Inc.10.14x 32.36x $3.1B $1.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
